Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Press Release
Written By Rich Foreman
 

RANCHO CORDOVA, Calif., September 7, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference.

If you are an institutional investor and would like to listen to the company’s on-demand presentation, please click on the following link to register for the conference: www.hcwevents.com. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the company.

A live webcast of the presentation will be available on the ThermoGenesis website at https://ThermoGenesis.com/investors/news-and-events/events-webcasts. An archived replay will be available for a period of 90 days after the conference.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 
Rich Foreman
Previous

Cryopreservation: A Key Element in the Successful Delivery of GMP Cell Therapies
Next

The Process of Bringing a Clinical Discovery to Market – From Concept to Commercial for Cell and Gene Therapy Products